Gregers Jungersen

Research areas

Through more than 25 years at the National Veterinary Institute, Technical University of Denmark and now SSI, I have worked with infectious disease immunology and development of vaccines. I have a special interest in tailored immune activation to induce local immunity at e.g. mucosal surfaces and in activation of an appropriate T cell immune response to fight intracellular infections. Ongoing projects are Vax2Muc with development of a vaccine against the gastric ulcer bacterium, Helicobacter pylori, and Blood2Gut with development of a new vaccine technology for induction of immunity in the gut after vaccination in the arm.

I have also worked with application of pigs as a supplementary large animal model for improved understanding of human immunology and immune therapy in the field of cancer and killer T cell activity.

Responsibilities

• Head of Section for Gastrointestinal Vaccine Research, Department of Infectious Disease Immunology

Selected publications

• Erbs G, Jakobsen JT, Schmidt ST, Christensen D, Bailey M, and Jungersen G. 2025. Retinoic acid-adjuvanted vaccine induces antigen-specific secretory IgA in the gut of newborn piglets. Vaccine, 46: 126672. doi.org/10.1016/j.vaccine.2024.126672
• Šťastná E, Erbs G, Skovgaard K, Jakobsen JT, Bailey M, Pedersen GK and Jungersen G. 2024. Effects of different immunomodulating liposome-based adjuvants and injection sites on immunogenicity in pigs. Microbes and Infection doi.org/10.1016/j.micinf.2024.105346
• Lybeck K, Tollefsen S, Mikkelsen H, Lundegaard C, Sjurseth SK, Aagaard C, Olsen I and Jungersen G. 2024. Selection of vaccine-candidate peptides from Mycobacterium avium subsp. paratuberculosis by in silico prediction, in vitro T-cell line proliferation and in vivo immunogenicity. Frontiers Immunology doi.org/10.3389/fimmu.2024.1297955
• Welner S, Ruggli N, Liniger M, Summerfield A, Larsen LE, Jungersen G. 2021. Reduced virus load in lungs of pigs challenged with porcine reproductive and respiratory syndrome virus after vaccination with virus replicon particles encoding conserved PRRSV cytotoxic T-cell epitopes. Vaccines, 9: 208. doi.org/10.3390/vaccines9030208.
• Overgaard NH, Principe DR, Schachtschneider KM, Jakobsen JT, Rund LA, Grippo PJ, Schook LB, Jungersen G. 2018. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β+ T Cells and Differentiated γδ T Cells Alongside a Regulatory Response Mediated by FOXP3+ T Cells and Immunoregulatory Molecules. Frontiers in Immunology 9: 1301.
• Ugolini M, Gerhard J, Burkert S, Jensen KJ, Georg P, Ebner F, Volkers S, Thada S, Dieter K, Bauer L, Schäfer A, Helbig E, Opitz B, Kurth F, Sur S, Dittrich N, Latha GS, Blander JM, Benn C, Gruber U, Gruber A, Hutloff A, Hartmann S, Boekschoten M, Müller M, Jungersen G, Schumann R, Suttorp N, Sander LE. 2018. Recognition of microbial viability via TLR8 promotes T follicular helper cell differentiation and vaccine responses. Nature Immunology 19: 386-396.

Complete list of publications: Gregers Jungersen's Bibliography